# Regeneron and Sanofi Q2 2026 financial performance

> Live situation record from CLSTR: https://clstr.news/situations/regeneron-and-sanofi-q2-2026-financial-performance
> Updated: 2026-08-17T06:27:17.000Z. Sources: 2. Developments: 2.

In the second quarter of 2026, both Regeneron Pharmaceuticals and Sanofi reported strong financial growth, largely attributed to the performance of the immunology drug Dupixent.

Regeneron reported revenue of $4.29 billion, exceeding Wall Street expectations, with Dupixent generating $6.0 billion in global net sales. The company also noted it had fully repaid the Sanofi Development Balance. 

Sanofi reported a 17.8 percent year-on-year revenue increase to 116 billion euros, with Dupixent contributing 52 billion euros. While experiencing growth, Sanofi announced it had discontinued four major drug development projects as part of a strategic review of its R&D activities.

## Timeline

### 2026-08-17: Sanofi reports strong Q2 2026 revenue growth driven by Dupixent

Sanofi reported a 17.8% revenue increase to 116 billion euros in Q2 2026, driven by Dupixent sales, despite discontinuing several R&D projects.

2 sources. https://clstr.news/cluster/sanofi-reports-strong-q2-2026-revenue-growth-driven-by-dupixent

### 2026-07-28: Regeneron Pharmaceuticals Q2 2026 earnings surpass estimates, driven by Dupixent sales

Regeneron beat Q2 2026 forecasts with $4.29 B revenue, $14.29 EPS, Dupixent sales up 38 % to $6 B, and high‑dose Eylea U.S. sales up 52 %, while fully repaying its Sanofi balance.

7 sources. https://clstr.news/cluster/mvb-financial-posts-q2-2026-earnings-with-123-million-net-income

---
Cite as: Regeneron and Sanofi Q2 2026 financial performance. CLSTR, https://clstr.news/situations/regeneron-and-sanofi-q2-2026-financial-performance